0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Discontinuation of Mycobacterium avium Complex Prophylaxis in Patients with Antiretroviral Therapy–Induced Increases in CD4+ Cell Count: A Randomized, Double-Blind, Placebo-Controlled Trial

Judith S. Currier, MD, MSc; Paige L. Williams, PhD; Susan L. Koletar, MD; Susan E. Cohn, MD, MPH; Robert L. Murphy, MD; Alison E. Heald, MD; Richard Hafner, MD; Ehab L. Bassily, MSc; Howard M. Lederman, MD, PhD; Charles Knirsch, MD, MPH; Constance A. Benson, MD; Hernan Valdez, MD; Judith A. Aberg, MD; and J. Allen McCutchan, MD
[+] Article and Author Information

for the AIDS Clinical Trials Group 362 Study Team


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 2000;133(7):493-503. doi:10.7326/0003-4819-133-7-200010030-00008
Text Size: A A A

Background: Patients infected with HIV who experience increases in CD4+ cell counts are at reduced risk for opportunistic infections. However, the safety of discontinuing prophylaxis against Mycobacterium avium complex has been uncertain.

Objective: To compare the rate of M. avium complex infection in patients with increased CD4+ cell counts who receive azithromycin and those receiving placebo.

Design: Randomized, double-blind, placebo-controlled trial.

Setting: 29 university-based clinical centers in the United States.

Participants: 643 HIV-1–infected patients with a previous CD4+ cell count less than 0.05 × 109 cells/L and a sustained increase to greater than 0.10 × 109 cells/L during antiretroviral therapy.

Intervention: Azithromycin, 1200 mg once weekly (n = 321), or matching placebo (n = 322).

Measurements: Mycobacterium avium complex cultures, CD4+ cell counts, and clinical evaluations for AIDS-defining illnesses and bacterial infections were done every 8 weeks. Plasma HIV-1 RNA levels were measured at 16-week intervals.

Results: During follow-up (median, 16 months), 2 cases of M. avium complex infection were reported among the 321 patients assigned to placebo (incidence rate, 0.5 event per 100 person-years [95% CI, 0.06 to 1.83 events per 100 person-years]) compared with no cases among the 322 patients assigned to azithromycin (CI, 0 to 0.92 events per 100 person-years), resulting in a treatment difference of 0.5 event per 100 person-years (CI, −0.20 to 1.21 events per 100 person-years) for placebo versus azithromycin. Both cases were atypical in that M. avium complex was localized to the vertebral spine. Patients receiving azithromycin were more likely than those receiving placebo to discontinue treatment with the study drug permanently because of adverse events (8% vs. 2%; hazard ratio, 0.24 [CI, 0.10 to 0.57]).

Conclusions: Prophylaxis against Mycobacterium avium complex can safely be withdrawn or withheld in adults with HIV infection who experience increases in CD4+ cell count while receiving antiretroviral therapy.

Figures

Grahic Jump Location
Figure.
Time to first azithromycin-preventable diagnosis (top) and first AIDS-defining illness (bottom) in patients receiving azithromycin prophylaxis (solid line) or placebo (dotted line).

Log-rank values comparing azithromycin with placebo were 0.25 (13 of 322 patients receiving azithromycin and 19 of 321 patients receiving placebo) for time to first azithromycin-preventable diagnosis and 0.016 (4 of 322 patients and 14 of 321 patients) for time to first AIDS-defining diagnosis.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)